StreetInsider.com News Articles

C4 Therapeutics (CCCC) PT Raised to $7 at Barclays

Thu, 26 Feb 2026 12:14:50 -0500

Barclays analyst Etzer Darout raised the price target on C4 Therapeutics (NASDAQ: CCCC) to $7.00 (from $5.00) while maintaining a Overweight rating.

The analyst comments "Phase 2 MOMENTUM initiated in 4L+ MM; additional cemsidomide analyses and combination plans expected mid-2026; BCMA combo initiating in 2Q as we continue to monitor the competitive landscape."

C4 Therapeutics (CCCC) PT Raised to $7 at Barclays

Thu, 26 Feb 2026 12:14:50 -0500

Barclays analyst Etzer Darout raised the price target on C4 Therapeutics (NASDAQ: CCCC) to $7.00 (from $5.00) while maintaining a Overweight rating.

TD Cowen Reiterates Buy Rating on C4 Therapeutics (CCCC)

Thu, 26 Feb 2026 10:56:15 -0500

TD Cowen analyst Tyler Van Buren reiterated a Buy rating on C4 Therapeutics (NASDAQ: CCCC).

The analyst comments "C4 has initiated its pivotal Phase II MOMENTUM study of cemsi + dex in 4L+ r/rMM, and a Phase Ib study combining cemsi with Elrexfio in the 2L+ is expected to initiate in Q2. The CELMoD class is also poised for a strong year, with an iberdomide + dex PDUFA in August that could mark the first class approval. KOLs expect CELMoDs to replace IMiDs as a MM backbone, which suggests a very large market."

For an analyst ratings summary and ratings history on

Form S-8 C4 Therapeutics, Inc.

Thu, 26 Feb 2026 07:52:00 -0500

si-local-file:///var/storage/secattach/20260226/26064595.html

Form S-8 C4 Therapeutics, Inc.

Thu, 26 Feb 2026 07:52:00 -0500

si-local-file:///var/storage/secattach/20260226/26064595.html

Form 10-K C4 Therapeutics, Inc. For: Dec 31

Thu, 26 Feb 2026 07:50:00 -0500

si-local-file:///var/storage/secattach/20260226/26064587.html

Form 10-K C4 Therapeutics, Inc. For: Dec 31

Thu, 26 Feb 2026 07:50:00 -0500

si-local-file:///var/storage/secattach/20260226/26064587.html

Form 8-K C4 Therapeutics, Inc. For: Feb 26

Thu, 26 Feb 2026 07:10:00 -0500

si-local-file:///var/storage/secattach/20260226/26064305.html

Form 8-K C4 Therapeutics, Inc. For: Feb 26

Thu, 26 Feb 2026 07:10:00 -0500

si-local-file:///var/storage/secattach/20260226/26064305.html

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Thu, 26 Feb 2026 07:00:00 -0500

Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later

Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 to Support Use in Earlier Lines of Multiple Myeloma Therapy

Second Degrader Designed and Delivered to Biogen Entered Clinical Development for Autoimmune Diseases

Strong Balance Sheet Provides Runway to the End of 2028; Cash, Cash Equivalents and Marketable Securities of $297.1 million as of December 31, 2025

WATERTOWN,

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Thu, 26 Feb 2026 07:00:00 -0500

Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later

Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 to Support Use in Earlier Lines of Multiple Myeloma Therapy

Second Degrader Designed and Delivered to Biogen Entered Clinical Development for Autoimmune Diseases

Strong Balance Sheet Provides Runway to the End of 2028; Cash, Cash Equivalents and Marketable Securities of $297.1 million as of December 31, 2025

WATERTOWN,

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Thu, 26 Feb 2026 07:00:00 -0500

Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later

Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 to Support Use in Earlier Lines of Multiple Myeloma Therapy

Second Degrader Designed and Delivered to Biogen Entered Clinical Development for Autoimmune Diseases

Strong Balance Sheet Provides Runway to the End of 2028; Cash, Cash Equivalents and Marketable Securities of $297.1 million as of December 31, 2025

WATERTOWN,

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Thu, 26 Feb 2026 07:00:00 -0500

Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later

Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 to Support Use in Earlier Lines of Multiple Myeloma Therapy

Second Degrader Designed and Delivered to Biogen Entered Clinical Development for Autoimmune Diseases

Strong Balance Sheet Provides Runway to the End of 2028; Cash, Cash Equivalents and Marketable Securities of $297.1 million as of December 31, 2025

WATERTOWN,

C4 Therapeutics (CCCC) PT Raised to $30 at Brookline Capital Markets

Mon, 23 Feb 2026 11:58:03 -0500

Brookline Capital Markets analyst Leah Rush Cann raised the price target on C4 Therapeutics (NASDAQ: CCCC) to $30.00 (from $20.00) while maintaining a Buy rating.

The analyst comments "Conclusions - The timing of the phase II cemsidomide/CFT7455 MOMENTUM trial initiation is as anticipated and further increases our conviction for the second quarter initiation of the phase Ib trial of cemsidomide in combination with elranatamab. The initiation of the MOMENTUM study follows positive phase I data for CFT7455 (cemsidomide) at the IMS meeting in September 2025. In addition, C4 plans to

C4 Therapeutics (CCCC) PT Raised to $30 at Brookline Capital Markets

Mon, 23 Feb 2026 11:58:03 -0500

Brookline Capital Markets analyst Leah Rush Cann raised the price target on C4 Therapeutics (NASDAQ: CCCC) to $30.00 (from $20.00) while maintaining a Buy rating.

C4 Therapeutics to Participate in Upcoming March Conferences

Mon, 23 Feb 2026 07:10:00 -0500

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in two upcoming March conferences.

TD Cowen 46^th Annual Healthcare Conference:
- Management will present and participate in a fireside chat on March 3, 2026, at 11:50 AM ET taking place in Boston, Massachusetts.

Barclays 28^th Annual Global Healthcare Conference:
- Management will participate in a fireside chat on March 10, 2026 at 8:00 AM ET taking place in Miami,

C4 Therapeutics to Participate in Upcoming March Conferences

Mon, 23 Feb 2026 07:10:00 -0500

TD Cowen 46^th Annual Healthcare Conference:
- Management will present and participate in a fireside chat on March 3, 2026, at 11:50 AM ET taking place in Boston, Massachusetts.

Barclays 28^th Annual Global Healthcare Conference:
- Management will participate in a fireside chat on March 10, 2026 at 8:00 AM ET taking place in Miami,

C4 Therapeutics to Participate in Upcoming March Conferences

Mon, 23 Feb 2026 07:10:00 -0500

TD Cowen 46^th Annual Healthcare Conference:
- Management will present and participate in a fireside chat on March 3, 2026, at 11:50 AM ET taking place in Boston, Massachusetts.

Barclays 28^th Annual Global Healthcare Conference:
- Management will participate in a fireside chat on March 10, 2026 at 8:00 AM ET taking place in Miami,

C4 Therapeutics to Participate in Upcoming March Conferences

Mon, 23 Feb 2026 07:10:00 -0500

TD Cowen 46^th Annual Healthcare Conference:
- Management will present and participate in a fireside chat on March 3, 2026, at 11:50 AM ET taking place in Boston, Massachusetts.

Barclays 28^th Annual Global Healthcare Conference:
- Management will participate in a fireside chat on March 10, 2026 at 8:00 AM ET taking place in Miami,

C4 Therapeutics begins phase 2 trial for multiple myeloma drug

Mon, 23 Feb 2026 07:00:17 -0500

C4 Therapeutics Inc. (NASDAQ: CCCC) announced it has dosed the first patient in its Phase 2 MOMENTUM trial evaluating cemsidomide combined with dexamethasone for treating relapsed/refractory multiple myeloma.

The Phase 2 MOMENTUM trial is an open-label, single-arm, multicenter study that will enroll approximately 100 patients to evaluate cemsidomide at the 100 microgram dose level. The trial targets patients requiring fourth-line treatment or later who have received at least three prior anti-myeloma regimens.

Cemsidomide is administered on a 14-day on, 14-day off dosing schedule, while dexamethasone is given once weekly. The primary endpoint measures overall response rate according to International Myeloma Working Group

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

Mon, 23 Feb 2026 07:00:00 -0500

Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027

Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM).

“Initiating the Phase 2 MOMENTUM trial, which builds upon the

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

Mon, 23 Feb 2026 07:00:00 -0500

Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027

Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM).

“Initiating the Phase 2 MOMENTUM trial, which builds upon the

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

Mon, 23 Feb 2026 07:00:00 -0500

Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027

Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM).

“Initiating the Phase 2 MOMENTUM trial, which builds upon the

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

Mon, 23 Feb 2026 07:00:00 -0500

Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027

Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM).

“Initiating the Phase 2 MOMENTUM trial, which builds upon the

Form 4 C4 Therapeutics, Inc. For: Feb 13 Filed by: Mossler Mark

Wed, 18 Feb 2026 17:05:00 -0500

si-local-file:///var/storage/secattach/20260218/26023375.html